For years, mental health patients and their doctors have often endured a trial-and-error process to figure out which drugs would best help them manage their illness. With the explosion of genetic testing, patients can now take a DNA test to receive psychiatric drug recommendations based on their genetic makeup. As these new tests take psychiatry by storm, however, NECIR's recent investigation found that the research behind them is scant, incomplete, or biased, and the potential for conflicts of interest is enormous.
Join NECIR's Senior Investigative Reporter Beth Daley, Huffington Post Healthy Living Editor Erin Schumaker, Dr. Joseph Goldberg of the Icahn School of Medicine at Mount Sinai, and Dr. Daniel Carlat of Tufts University School of Medicine to learn more about this emerging industry in mental health care.
You can leave a question now, and join us live from 3:30pm to 4:30pm ET on Wednesday, October 7th for a live discussion on psychiatric genetic testing.